Targeting CDK7 to overcome hypomethylating agent resistance in acute myeloid leukemia

Abstract excerpt

<title>Abstract</title> <p> Purpose Hypomethylating agents (HMAs), such as azacitidine and decitabine, are widely used in elderly or medically unfit patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). However, most patients eventually develop primary or acquired resistance, and outcomes following HMA failure remain poor, particularly in transplantation-ineligible patients. This study e...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• Antineoplastic Agents
• Antineoplastic Combined Chemotherapy Protocols
• Drug Design
• Drug Resistance, Neoplasm
• Leukemia, Myeloid, Acute
• Leukemia, Myelomonocytic, Chronic
• Mutation

Identifiers and source

Literature Corpus work

41ecc41e-e69a-58fd-970e-409b2c83d838

DOI

10.21203/rs.3.rs-9638666/v1